Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1) that exhibits antitumor activity. Pacmilimab achieves tumor-selective activation by exposing the PD-L1 binding site through cleavage by tumor microenvironment-specific proteases. Upon activation, it binds to PD-L1 with high affinity, blocking the PD-1/PD-L1 pathway, lifting immune suppression, and restoring T-cell antitumor activity. Pacmilimab is indicated for the study of solid tumors.

帕克米利单抗, CX-072, CX072

Human

Monoclonal

Unconjugated